Follow
Job Title: Senior Director Portfolio Integration Lead - HematologyDescriptionFor candidates seeking to be located at our Stevenage site this role will temporarily be based at Stevenage. However the Company plans to relocate its offices to Cambridge UK. The location of this role will t
Job Title: Senior Director Portfolio Integration Lead - HematologyDescriptionFor candidates seeking to be located at our Stevenage site this role will temporarily be based at Stevenage. However the Company plans to relocate its offices to Cambridge UK. The location of this role will t
Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol
Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol
Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol
Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol
Central Region: TX CO AZ UT OK AR WY and portions of NM NV KS WA ID IAViiV Healthcare is a global specialty HIV company the only one that is 100% focused on researching and delivering new medicines for people living with and at risk of HIV. ViiV is highly mission-driven in our unrelen
Central Region: TX CO AZ UT OK AR WY and portions of NM NV KS WA ID IAViiV Healthcare is a global specialty HIV company the only one that is 100% focused on researching and delivering new medicines for people living with and at risk of HIV. ViiV is highly mission-driven in our unrelen
Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol
Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol
Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol
Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol
Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol
Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol
Business IntroductionAt GSK we have bold ambitions for patients aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines combining our understanding of the immune system with cutting-edg
Business IntroductionAt GSK we have bold ambitions for patients aiming to positively impact the health of 2.5 billion people by the end of the decade. Our R&D focuses on discovering and delivering vaccines and medicines combining our understanding of the immune system with cutting-edg
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Business IntroductionGSK remains committed to achieving bold commercial ambitions for the future. By 2031 we aim to deliver 40 billion in annual sales leveraging our existing strong performance momentum to significantly increase our positive impact on the health of billions of patient
Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol
Welcome to Haleon. Were a purpose-driven world-class consumer company putting everyday health in the hands of just three years since our launch weve grown evolved and are now entering an exciting new chapter one filled with bold ambitions and enormous opportunity.Our trusted portfol
